Lilly to pay up to $7.8 billion to buy a company developing a narcolepsy drug
The company, which is flush with cash from sales of its market-leading GLP-1 franchise, has been an active dealmaker.
The company, which is flush with cash from sales of its market-leading GLP-1 franchise, has been an active dealmaker.